NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping ...

(Reuters) -Shares of Metsera fell over 15% in premarket trading on Monday, after the weight-loss drug developer accepted a ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

Pfizer (PFE) wins Metsera (MTSR) buyout after a heated bidding war with Novo Nordisk (NVO), securing a $10B deal for the ...

Nov 5 (Reuters) - Pfizer (PFE.N) plans to sweeten its bid for Metsera (MTSR.O), a person familiar with the matter told ...

A bidding war over U. biotech Metsera was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 ...

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.

Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.